Organon licenses MetaCore from GeneGo
GeneGo, Inc., a leading provider of software and databases for systems biology, announced that N.V. Organon has licensed MetaCoreTM, GeneGo’s platform for mining of high-throughput experimental data in the context of biological networks and human diseases. MetaCore is an enterprise platform being installed in the majority of the top Pharmaceutical companies internationally. The suite includes a comprehensive, manually curated database which covers all levels of human cellular functionality, as well as rat, mouse, fly, worm and yeast orthologs, and functional information on over 3,000 human diseases and thousands of drugs connected with pathway targets Organon plans to use MetaCore in pre-clinical research across various therapeutic areas and departments.
“We evaluated several platforms and decided that MetaCore was the best fit for our current needs at Organon. We are very much looking forward to working closely with GeneGo,” said Dr. Peter Groenen, senior research scientist at Organon.
“We are happy that Organon decided to choose MetaCore™ as their systems biology solution”, said Julie Bryant, VP of business development at GeneGo. “In addition to extensive content and data mining tools, we emphasize flexible open architecture compatible with different informatics environments and third-party software. We are glad that this strategy is appreciated by researchers in different areas of drug discovery. Organon is one of the leading companies focused on hormone therapy, fertility and mental health and we look forward to working closely with them on making advances in these areas using systems biology tools.”
About GeneGo
GeneGo is a Michigan-based company developing systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolites, phenotypic data etc.) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of biological pathways and networks. GeneGo’s flagship product, MetaCore(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug(TM) is designed for prediction of human metabolism and toxicity for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore(TM). For more information, please visit the company’s web site at http://www.genego.com .
MetaCore(TM) and MetaDrug(TM) are trademarks of GeneGo, Inc.
About Organon
Organon – with shared head offices in Roseland, NJ, USA and Oss, The Netherlands – creates, manufactures and markets prescription medicines that improve the health and quality of human life. Through a combination of independent growth and business partnerships, Organon strives to remain or become one of the leading pharmaceutical companies in each of its core therapeutic fields: reproductive medicine, psychiatry and anesthesia. Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary. Organon is the human health care business unit of Akzo Nobel.
